Zollinger‑Ellison (Gastrinoma) Syndrome
Overview
Zollinger‑Ellison syndrome (ZES) is a rare disorder caused by one or more gastrin‑secreting tumors (gastrinomas) that most often arise in the pancreas or the duodenum. The excess gastrin stimulates the stomach to produce large volumes of gastric acid, leading to severe peptic ulcer disease and a host of digestive symptoms.
Who it affects: ZES can develop at any age but most cases are diagnosed between 30 and 60 years old. Men and women are affected equally. About 25 % of patients have an inherited form called multiple endocrine neoplasia type 1 (MEN‑1), which also predisposes to tumors of the parathyroid and pituitary glands.
Prevalence: Sporadic gastrinomas occur in approximately 1–3 persons per million per year, while the overall prevalence of ZES (including MEN‑1‑related cases) is estimated at 0.5–1 per 100,000 people worldwide (CDC). Because many cases remain undiagnosed for years, the true number may be slightly higher.
Symptoms
The hallmark of ZES is hyper‑acid production, but the clinical picture varies widely. Symptoms can be intermittent or continuous and often mimic other gastrointestinal conditions.
Gastro‑intestinal symptoms
- Recurrent or refractory peptic ulcers – often multiple, located in atypical sites (duodenum, jejunum, or even the colon).
- Abdominal pain – burning or cramping pain that may improve with food or antacids.
- Diarrhea – watery, sometimes greasy stools caused by acid inactivation of pancreatic enzymes.
- Steatorrhea (fatty stools) – malabsorption of fats due to pancreatic enzyme dysfunction.
- Nausea & vomiting – can be triggered by ulcer complications or gastric outlet obstruction.
- Weight loss – secondary to malabsorption, chronic diarrhea, and decreased appetite.
Systemic & extra‑intestinal symptoms
- Heartburn / gastro‑oesophageal reflux disease (GERD) – from excess acid spilling into the esophagus.
- Fatigue & anemia – chronic blood loss from ulcerations.
- Osteopenia/osteoporosis – long‑term acid excess can impair calcium absorption.
- MEN‑1 manifestations (if present) – hyperparathyroidism (hypercalcemia, kidney stones) and pituitary adenomas (headaches, visual changes).
Causes and Risk Factors
Primary causes
- Sporadic gastrinoma – a solitary neuroendocrine tumor arising de novo in the pancreas or duodenum.
- MEN‑1 associated gastrinoma – an inherited mutation in the MEN1 tumor suppressor gene on chromosome 11q13. Patients often develop multiple small gastrinomas.
Risk factors
- Family history of MEN‑1 or known MEN1 gene mutation.
- Previous diagnosis of other MEN‑1 tumors (parathyroid, pituitary).
- Chronic gastritis or Helicobacter pylori infection does not cause ZES, but can coexist and worsen ulcer disease.
Diagnosis
Diagnosing Zollinger‑Ellison syndrome requires a combination of biochemical testing, imaging, and sometimes endoscopic evaluation.
1. Laboratory tests
- Fasting serum gastrin level – > 1000 pg/mL (normal < 100 pg/mL) strongly suggests a gastrinoma, especially when gastric pH < 2.0. Values between 100‑1000 pg/mL need further confirmation.
- Secretin stimulation test – intravenous secretin normally suppresses gastrin; in gastrinoma patients, gastrin paradoxically rises ≥ 120 pg/mL after secretin.
- Gastric pH measurement – persistent acidity (pH < 2) despite high gastrin supports the diagnosis.
- Additional labs: CBC (to assess anemia), serum calcium, and parathyroid hormone (if MEN‑1 is suspected).
2. Imaging studies
- Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – high sensitivity for locating neuroendocrine tumors.
- Multiphasic contrast‑enhanced CT or MRI – useful for anatomic detail, surgical planning, and detecting liver metastases.
- Endoscopic ultrasound (EUS) – excellent for small pancreatic lesions (< 2 cm) and allows fine‑needle aspiration for histology.
3. Endoscopic evaluation
- Upper endoscopy (EGD) – identifies multiple or refractory ulcers, allows biopsy to rule out H. pylori, and may detect antral gastritis.
Diagnostic criteria summary
- Fasting gastrin > 1000 pg/mL with gastric pH < 2, or
- Fasting gastrin 100‑1000 pg/mL + positive secretin stimulation test, and
- Imaging confirming a gastrinoma (or MEN‑1‑related tumor).
Treatment Options
Therapy aims to control acid hypersecretion, remove or shrink the tumor, and monitor for recurrence or metastasis.
1. Acid‑suppression therapy (first line)
- Proton pump inhibitors (PPIs) – high‑dose omeprazole, esomeprazole, or pantoprazole are the mainstay. Doses often exceed standard ulcer doses (e.g., omeprazole 60–80 mg daily) and are titrated to keep gastric pH > 4.
- Histamine‑2 receptor antagonists (H2RAs) – may be added for breakthrough symptoms but are less effective alone.
- Long‑term PPI use should be monitored for potential side effects (e.g., B12 deficiency, hypomagnesemia).
2. Surgical management
- Curative resection – preferred for solitary, localized gastrinomas. Enucleation or pancreaticoduodenectomy (Whipple) may be performed based on tumor size and location.
- Debulking surgery – for metastatic disease; removal of > 90 % of tumor burden can improve symptom control.
- Liver metastases – may be resected, ablated, or treated with embolization.
3. Medical therapies for unresectable or metastatic disease
- Somatostatin analogs (octreotide, lanreotide) – suppress gastrin release and may shrink tumors.
- Targeted radiotherapy – peptide receptor radionuclide therapy (PRRT) with ^177Lu‑DOTATATE is effective for somatostatin‑receptor‑positive disease.
- Systemic chemotherapy (e.g., streptozocin + 5‑FU or capecitabine/temozolomide) – reserved for aggressive, progressive disease.
- mTOR inhibitor (everolimus) – approved for progressive pancreatic neuroendocrine tumors.
4. Lifestyle & supportive measures
- Small, frequent meals to reduce acid load.
- Avoidance of alcohol, caffeine, nicotine, and NSAIDs, which can aggravate ulcer disease.
- Calcium and vitamin D supplementation if on long‑term PPIs.
- Vaccination against Helicobacter pylori reinfection if previously treated.
Living with Zollinger’s Gastrinoma Syndrome
Medication adherence
- Take PPIs exactly as prescribed—most patients need lifelong therapy.
- Set reminders or use a pill organizer to prevent missed doses.
Monitoring & follow‑up
- Serum gastrin and gastric pH should be checked every 6–12 months.
- Imaging (CT/MRI or somatostatin scan) is advised annually for the first 3 years, then every 1–2 years, or sooner if symptoms change.
- For MEN‑1 patients, add regular screening for parathyroid (calcium, PTH) and pituitary (MRI, visual field testing) lesions.
Nutrition
- High‑protein, low‑fat diet can reduce steatorrhea.
- Include probiotic‑rich foods (yogurt, kefir) to support gut health.
- Stay hydrated; consider oral rehydration solutions if diarrhea is frequent.
Psychosocial support
- Connect with support groups (e.g., NET (Neuroendocrine Tumor) patient organizations).
- Consider counseling or cognitive‑behavioral therapy to manage chronic illness stress.
Prevention
Because ZES is primarily a tumor‑driven condition, primary prevention is limited. However, some strategies can lower the impact of the disease or its complications:
- Genetic counseling for families with known MEN‑1 mutations; predictive testing can guide early surveillance.
- Avoid known ulcer‑aggravating agents (smoking, excessive NSAIDs, heavy alcohol use).
- Early treatment of Helicobacter pylori if present, to reduce additive ulcer burden.
- Regular medical check‑ups for individuals with MEN‑1 or other endocrine neoplasia syndromes.
Complications
If left untreated or inadequately managed, ZES can lead to serious health problems:
- Refractory peptic ulcers – may perforate, bleed, or cause gastric outlet obstruction.
- Gastro‑intestinal bleeding – presenting as melena or hematemesis; can cause severe anemia.
- Malabsorption & nutritional deficiencies – especially fat‑soluble vitamins (A, D, E, K) and calcium.
- Metastatic disease – liver, lymph nodes, or bone metastases occur in 30‑50 % of sporadic cases.
- Electrolyte disturbances – chronic diarrhea may cause hypokalemia, metabolic alkalosis.
- Bone disease – secondary osteoporosis from chronic acid load and PPI‑related calcium malabsorption.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden, severe abdominal pain that does not improve with antacids.
- Vomiting blood (hematemesis) or passing black, tarry stools (melena).
- Profuse, watery diarrhea leading to dizziness, fainting, or rapid heart rate.
- High fever (> 38.5 °C / 101 °F) with abdominal tenderness – possible perforation or infection.
- Sudden shortness of breath, chest pain, or fainting – could signal massive bleeding or sepsis.
These signs may indicate ulcer perforation, severe gastrointestinal bleeding, or sepsis, all of which require immediate medical intervention.
Key Take‑aways
- Zollinger‑Ellison syndrome is a rare but treatable cause of severe hyperacidic peptic ulcer disease.
- High‑dose PPIs control symptoms; surgery offers a potential cure when the tumor is localized.
- Regular monitoring, genetic counseling for MEN‑1 families, and lifestyle modifications are essential for long‑term health.
- Prompt emergency care for bleeding, perforation, or severe diarrhea can save lives.
For personalized guidance, always discuss your situation with a gastroenterologist or an endocrinologist experienced in neuroendocrine tumors.
References:
- Mayo Clinic. “Zollinger‑Ellison syndrome.” https://www.mayoclinic.org (accessed June 2026).
- National Institutes of Health. “Neuroendocrine Tumors (NETs) – Diagnosis and Treatment.” https://www.cancer.gov.
- American Cancer Society. “Gastrinoma (Zollinger‑Ellison Syndrome).” https://www.cancer.org.
- World Health Organization. “Neuroendocrine Tumors.” https://www.who.int.
- Cleveland Clinic. “Zollinger‑Ellison Syndrome – Treatment Options.” https://my.clevelandclinic.org.
- Yao JC, et al. “One hundred years after the discovery of gastrinomas: contemporary epidemiology and outcomes.” *J Clin Endocrinol Metab.* 2020;105(2):471‑480.